Patents by Inventor Roger Chammas

Roger Chammas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound for modulating rlr, tlr, oas and/or oncostatin m pathways, use thereof for preparing a medicine, composition, method for modulating said pathways and method of treatment
    Patent number: 12329806
    Abstract: The invention falls within the fields of pharmaceutical sciences, immunology and methods of treatment of cancer Methods. More specifically, the invention relates to a compound for modulating one or more innate immune pathways selected from RLR, TLR, OAS and/or oncostatin M, said compound being amblyomin-×or peptides derived from amblyomin-X. Use of said compound for preparing medicines; a pharmaceutical composition comprising said compound, a method for modulating said pathways in vitro and a method of treatment are also described.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 17, 2025
    Assignee: Instituto Butantan
    Inventors: Ana Marisa Chudzinski Tavassi, Roger Chammas, Maurício Barbugiani Goldfeder, Carlos Deocesano Pereira, Flávio Linchtenstein, Jean Gabriel De Souza, Katia Luciano Pereira Morais
  • COMPOUND FOR MODULATING RLR, TLR, OAS AND/OR ONCOSTATIN M PATHWAYS, USE THEREOF FOR PREPARING A MEDICINE, COMPOSITION, METHOD FOR MODULATING SAID PATHWAYS AND METHOD OF TREATMENT
    Publication number: 20220370577
    Abstract: The invention falls within the fields of pharmaceutical sciences, immunology and methods of treatment of cancer Methods. More specifically, the invention relates to a compound for modulating one or more innate immune pathways selected from RLR, TLR, OAS and/or oncostatin M, said compound being amblyomin-×or peptides derived from amblyomin-X. Use of said compound for preparing medicines; a pharmaceutical composition comprising said compound, a method for modulating said pathways in vitro and a method of treatment are also described.
    Type: Application
    Filed: November 22, 2019
    Publication date: November 24, 2022
    Inventors: Ana Marisa Chudzinski Tavassi, Roger Chammas, Maurício Barbugiani Goldfeder, Carlos Deocesano Pereira, Flávio Linchtenstein, Jean Gabriel De Souza, Katia Luciano Pereira Morais
  • Method of treating bone or prostate cancer with selective bradykinin B1 receptor antagonists
    Patent number: 7932228
    Abstract: Provided is a method for the use of a bradykinin B1 receptor antagonist of formula I: X-CO-Aaa0-Aaa1-Aaa2-Aaa3-Gly-?(Me)Phe-Ser-D-?Nal-Aaa8-OH (I) or a pharmaceutically acceptable salt or hydrate thereof wherein: X is CnH2n+1 or CiH2i—C6H5, where n is an integer from 1 to 3, and i is an integer from 0 to 3; Aaa0 is Lys, Orn or Cit; Aaa1 is Arg or Cit, and preferably Arg; Aaa2 is Oic, Hyp or Pro, and preferably Oic; Aaa3 is Pro or Oic, and preferably Pro; and Aaa8 is Ile, Leu or Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of the compound to a patient in need of such treatment. Also provided are compositions containing such antagonists and their thereof.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: April 26, 2011
    Assignee: Societe de Commercialisation des Produits de la Recherche Applique Socpra Sciences Sante et Humaines S.E.C.
    Inventors: François Nantel, Roger Chammas, Pierre Sirois, Bruno Joseph Battistini
  • Method of treating cancer and neuropathic complications induced by chemotherapeutic agents using selective Bradykinin B1 receptor antagonists
    Publication number: 20070015715
    Abstract: The present invention relates to a method for the use of a bradykinin B1 receptor antagonist of formula I: X—CO-Aaa0-Aaa1-Aaa2-Aaa3-Gly-?(Me)Phe-Ser-D-?Nal-Aaa8-OH??(I) or a pharmaceutically acceptable salt or hydrate thereof wherein: X is CnH2n+1 or CiH2i—C6H5, where n is an integer from 1 to 3, and i is an integer from 0 to 3; Aaa0 is Lys, Orn or Cit; Aaa1 is Arg or Cit, and preferably Arg; Aaa2 is Oic, Hyp or Pro, and preferably Oic; Aaa3 is Pro or Oic, and preferably Pro; and Aaa8 is Ile, Leu, Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of said compound to a patient in need of such treatment. The present invention also relates to compositions containing such antagonists and the uses thereof.
    Type: Application
    Filed: June 12, 2006
    Publication date: January 18, 2007
    Applicant: Universite de Sherbrooke
    Inventors: Francois Nantel, Roger Chammas, Pierre Sirois, Bruno Battistini